Hypothesis

Rapamycin extends lifespan not only by triggering conserved famine‑response programs but also by directly correcting aberrant hexosamine biosynthetic pathway (HBP) flux, thereby restoring O‑GlcNAc cycling homeostasis and alleviating proteotoxic stress in diabetic aging.

Mechanistic Rationale

• mTORC1 activity stimulates glutamine‑fructose‑6‑phosphate amidotransferase (GFAT)‑driven HBP flux, increasing UDP‑GlcNAc levels that drive excessive O‑GlcNAc transferase (OGT) activity and disrupt O‑GlcNAcase (OGA) balance【1†L1-L3】.
• Elevated O‑GlcNAcylation impairs proteasome and autophagy flux, promotes tau aggregation, and compromises cardioprotective glycosaminoglycan turnover【2†L1-L3】【3†L1-L2】.
• Rapamycin inhibits mTORC1, which reduces GFAT transcription and translation via decreased S6K‑mediated signaling, lowering UDP‑GlcNAc synthesis【4†L1-L2】.
• Concomitantly, rapamycin‑induced autophagy (ATF4‑Sestrin2‑dependent) clears accumulated UDP‑GlcNAc and mis‑O‑GlcNAcylated proteins, resetting the OGT/OGA activity ratio【5†L1-L3】.
• This dual action—nutrient‑sensing suppression plus autophagic clearance—distinguishes rapamycin from caloric restriction, which lowers substrate availability without directly targeting HBP enzyme expression.

Testable Predictions

1. In diabetic (db/db) mice, chronic rapamycin treatment will decrease hepatic and cerebral GFAT mRNA and protein levels relative to vehicle‑treated controls.
2. Correspondingly, UDP‑GlcNAc concentrations will fall, and the OGT/OGA activity ratio will shift toward baseline levels observed in non‑diabetic aged mice.
3. Restored O‑GlcNAc homeostasis will reduce insoluble tau aggregates in hippocampal lysates and improve systolic function in diabetic hearts.
4. Genetic or pharmacological inhibition of autophagy (e.g., Atg7 knockout or chloroquine co‑treatment) will abolish rapamycin’s effects on HBP flux and O‑GlcNAcylation, demonstrating autophagy dependence.
5. Caloric restriction matched for caloric intake will lower blood glucose but will not significantly alter GFAT expression or UDP‑GlcNAc pools, confirming a mechanistic divergence.

Experimental Design

• Animal groups: (i) Wild‑type aged, (ii) db/db untreated, (iii) db/db + rapamycin (14 ppm diet), (iv) db/db + rapamycin + autophagy inhibitor, (v) db/db + caloric restriction (40 % reduction).
• Readouts (after 3 months): GFAT Western blot/qPCR, LC‑MS UDP‑GlcNAc quantification, OGT/OGA activity assays, soluble/insoluble tau ELISA, autophagic flux (LC3‑II/p62), echocardiographic fractional shortening, survival curves.
• Statistical plan: Two‑way ANOVA with post‑hoc Tukey; n ≥ 10 per group to detect 20 % changes with 80 % power.

Falsifiability

If rapamycin fails to reduce GFAT expression or UDP‑GlcNAc levels, or if autophagy blockade does not prevent the normalization of O‑GlcNAc cycling, the hypothesis is refuted. Conversely, a selective reduction of HBP flux coupled with improved proteostasis would support the claim that rapamycin’s lifespan benefits stem from direct correction of a nutrient‑sensing damage pathway, not merely from mimicking scarcity.